STUDY | ADMIN | CCADMIN | ACCR. GOAL |
R E G |
O P E N |
ARM | TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
---|---|---|---|---|---|---|---|---|---|---|---|---|
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | PEOLC | 817 | 1 | T | 0 Screening | 329 | 12 | 1 | 0 | 0 | 0 | |
329 | 12 | 1 | 0 | 0 | 0 | |||||||
2 | T | 1 Carvedilol | 74 | 5 | 0 | 0 | 0 | 0 | ||||
2 No prophylaxis | 81 | 7 | 1 | 0 | 0 | 0 | ||||||
3 Observation | 155 | 0 | 0 | 0 | 0 | 0 | ||||||
310 | 12 | 1 | 0 | 0 | 0 | |||||||
S1703-Met Breast, STM-monitoring v Usual Care | CCD | SXQOL | 739 | 1 | Y | 0 Screening | 509 | 71 | 35 | 20 | 5 | 0 |
509 | 71 | 35 | 20 | 5 | 0 | |||||||
2 | Y | 1 Control (Usual Care) | 172 | 26 | 16 | 7 | 2 | 1 | ||||
2 Intervention (STMDDM) | 174 | 30 | 17 | 8 | 2 | 0 | ||||||
346 | 56 | 33 | 15 | 4 | 1 | |||||||
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | GU | SXQOL | 1273 | 1 | Y | 0 Induction SST | 820 | 122 | 65 | 33 | 6 | 2 |
820 | 122 | 65 | 33 | 6 | 2 | |||||||
2 | Y | 1 Standard Systemic Therapy Only | 288 | 37 | 19 | 11 | 3 | 0 | ||||
2 SST + Surgery/RT | 291 | 42 | 23 | 13 | 6 | 2 | ||||||
579 | 79 | 42 | 24 | 9 | 2 | |||||||
S1803-MM, Maintenance, Len vs Len/Dara | MMYEL | SXQOL | 1420 | 1 | Y | 0 Screening | 1283 | 142 | 130 | 72 | 19 | 6 |
1283 | 142 | 130 | 72 | 19 | 6 | |||||||
2 | Y | 1 Lenalidomide | 590 | 66 | 58 | 36 | 7 | 2 | ||||
2 Lenalidomide + Daratumumab | 585 | 71 | 64 | 36 | 9 | 4 | ||||||
1175 | 137 | 122 | 72 | 16 | 6 | |||||||
3 | Y | 3 Continue Lenalidomide | 27 | 12 | 2 | 0 | 0 | 0 | ||||
4 Stop Lenalidomide | 29 | 15 | 4 | 2 | 0 | 0 | ||||||
5 Continue Lenalidomide + Dara | 67 | 28 | 12 | 7 | 1 | 0 | ||||||
6 Stop Lenalidomide + Dara | 67 | 26 | 13 | 6 | 2 | 0 | ||||||
190 | 81 | 31 | 15 | 3 | 0 | |||||||
S1827-SCLC, MRI Surveillance +/- PCI | LUNG | SXQOL | 668 | 1 | Y | 1 PCI + MRI brain surveillance | 113 | 34 | 19 | 8 | 2 | 0 |
2 MRI brain surveillance | 115 | 36 | 22 | 8 | 3 | 0 | ||||||
228 | 70 | 41 | 16 | 5 | 0 | |||||||
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship | CCD | 326 | 1 | Y | 1 Financial Navigation | 130 | 87 | 46 | 21 | 7 | 1 | |
2 Control | 134 | 88 | 47 | 21 | 10 | 2 | ||||||
264 | 175 | 93 | 42 | 17 | 3 | |||||||
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | LUNG | SXQOL | 480 | 1 | Y | 1 Atezolizumab and SBRT | 197 | 83 | 47 | 20 | 9 | 2 |
2 SBRT | 192 | 80 | 39 | 22 | 3 | 0 | ||||||
389 | 163 | 86 | 42 | 12 | 2 | |||||||
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP | LYMPH | SXQOL | 422 | 1 | Y | 1 CC-486 + R-miniCHOP | 54 | 23 | 11 | 7 | 2 | 1 |
2 R-miniCHOP | 54 | 26 | 14 | 7 | 3 | 0 | ||||||
108 | 49 | 25 | 14 | 5 | 1 | |||||||
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | LEUK | SXQOL | 247 | 1 | Y | 1 Delayed V-O | 38 | 12 | 6 | 3 | 2 | 0 |
2 Early V-O | 71 | 23 | 17 | 8 | 3 | 0 | ||||||
109 | 35 | 23 | 11 | 5 | 0 | |||||||
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed | SXQOL | 540 | 1 | Y | 1 Active Symptom Monitoring + Patient Education | 176 | 151 | 89 | 41 | 6 | 2 | |
2 Patient Education | 177 | 155 | 91 | 42 | 9 | 4 | ||||||
353 | 306 | 180 | 83 | 15 | 6 | |||||||
S2013-I-CHECKIT: ICI toxicity risk prediction study | SXQOL | 2062 | 1 | T | 1 Observation Arm | 2084 | 860 | 370 | 81 | 0 | 0 | |
2084 | 860 | 370 | 81 | 0 | 0 | |||||||
S2108CD-Genomic Tumor Board vs Usual Practice | CCD | 1182 | 1 | Y | 1 Usual Practice | 496 | 265 | 139 | 73 | 24 | 7 | |
2 EGTB Intervention | 592 | 370 | 154 | 72 | 27 | 7 | ||||||
1088 | 635 | 293 | 145 | 51 | 14 | |||||||
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | SXQOL | 777 | 1 | Y | 1 Cryocompression | 58 | 56 | 36 | 17 | 6 | 0 | |
2 Continuous Compression | 57 | 56 | 35 | 16 | 4 | 1 | ||||||
3 Low Cyclic Compression | 61 | 57 | 36 | 19 | 8 | 4 | ||||||
176 | 169 | 107 | 52 | 18 | 5 | |||||||
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | BREAST | SXQOL | 960 | 1 | Y | 1 Tissue for MammaPrint testing | 112 | 112 | 106 | 64 | 21 | 6 |
112 | 112 | 106 | 64 | 21 | 6 | |||||||
2 | Y | 2 SOC Chemotherapy | 15 | 15 | 15 | 12 | 3 | 0 | ||||
3 SOC Chemotherapy + Durvalumab | 15 | 15 | 15 | 11 | 3 | 0 | ||||||
30 | 30 | 30 | 23 | 6 | 0 | |||||||
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | LYMPH | SXQOL | 227 | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 7 | 7 | 6 | 5 | 0 | 0 |
4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 10 | 6 | 2 | 0 | 0 | ||||||
5 Zanubrutinib (Arm 3) Dose Level 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
19 | 19 | 14 | 9 | 2 | 2 | |||||||
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | MMYEL | SXQOL | 510 | 1 | Y | 1 VRD-R | 10 | 10 | 6 | 3 | 1 | 0 |
2 DRD-R | 11 | 11 | 7 | 4 | 2 | 1 | ||||||
3 DRD-DR | 9 | 9 | 7 | 4 | 0 | 0 | ||||||
30 | 30 | 20 | 11 | 3 | 1 | |||||||
S2212-Breast, TNBC, Neoadj Chemo + Pembro | BREAST | SXQOL | 2400 | 1 | Y | 1 Carbo + Paclitaxel + Pembro -> AC + Pembro | 103 | 103 | 85 | 52 | 14 | 3 |
2 Carbo + Docetaxel + Pembro | 103 | 103 | 84 | 52 | 15 | 3 | ||||||
206 | 206 | 169 | 104 | 29 | 6 | |||||||
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | MMYEL | SXQOL | 338 | 1 | Y | 0 Induction | 1 | 1 | 1 | 1 | 1 | 0 |
1 | 1 | 1 | 1 | 1 | 0 | |||||||
2 | Y | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
3 | Y | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | GI | SXQOL | 224 | 1 | Y | 2 Paclitaxel + Ramucirumab | 1 | 1 | 1 | 1 | 1 | 0 |
1 | 1 | 1 | 1 | 1 | 0 | |||||||
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | BREAST | SXQOL | 1 | E | 44 | 15 | 4 | 2 | 0 | 0 | ||
44 | 15 | 4 | 2 | 0 | 0 | |||||||
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | BREAST | SXQOL | 1 | E | 8 | 8 | 4 | 3 | 0 | 0 | ||
8 | 8 | 4 | 3 | 0 | 0 | |||||||
A021806-Pancreas, Perioperative vs Adjuvant Chemo | GI | SXQOL | 0 | E | 36 | 9 | 2 | 1 | 0 | 0 | ||
36 | 9 | 2 | 1 | 0 | 0 | |||||||
1 | E | 30 | 8 | 2 | 1 | 0 | 0 | |||||
30 | 8 | 2 | 1 | 0 | 0 | |||||||
A022001-PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM | GI | SXQOL | 1 | E | 2 | 1 | 1 | 0 | 0 | 0 | ||
2 | 1 | 1 | 0 | 0 | 0 | |||||||
A022004-Colon, Stg II-III, Encor+Cetux vs SOC | GI | SXQOL | 0 | E | 7 | 7 | 7 | 4 | 3 | 1 | ||
7 | 7 | 7 | 4 | 3 | 1 | |||||||
1 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
A032103-Urothelial, All Stg, MRD-Based Adj Tx | GU | SXQOL | 0 | E | 2 | 2 | 2 | 1 | 1 | 0 | ||
2 | 2 | 2 | 1 | 1 | 0 | |||||||
1 | E | 1 | 1 | 1 | 1 | 0 | 0 | |||||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | LYMPH | SXQOL | 1 | E | 7 | 7 | 6 | 4 | 2 | 2 | ||
7 | 7 | 6 | 4 | 2 | 2 | |||||||
2 | E | 1 | 1 | 0 | 0 | 0 | 0 | |||||
1 | 1 | 0 | 0 | 0 | 0 | |||||||
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | LUNG | SXQOL | 1 | E | 79 | 17 | 10 | 4 | 3 | 2 | ||
79 | 17 | 10 | 4 | 3 | 2 | |||||||
A211901-Cancer survivors who smoke, txt cessation | SURV | 1 | E | 10 | 10 | 7 | 6 | 1 | 0 | |||
10 | 10 | 7 | 6 | 1 | 0 | |||||||
ACCL16N1-Guideline Consistent Treatment AYA ALL | CCD | 1 | T | 54 | 0 | 0 | 0 | 0 | 0 | |||
54 | 0 | 0 | 0 | 0 | 0 | |||||||
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | LYMPH | SXQOL | 1 | E | 19 | 19 | 8 | 3 | 1 | 0 | ||
19 | 19 | 8 | 3 | 1 | 0 | |||||||
2 | E | 14 | 14 | 6 | 2 | 1 | 0 | |||||
14 | 14 | 6 | 2 | 1 | 0 | |||||||
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx | OTHER | SXQOL | 1 | E | 1 | 1 | 1 | 0 | 0 | 0 | ||
1 | 1 | 1 | 0 | 0 | 0 | |||||||
2 | E | 1 | 1 | 1 | 0 | 0 | 0 | |||||
1 | 1 | 1 | 0 | 0 | 0 | |||||||
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | MMYEL | SXQOL | 0 | E | 46 | 17 | 2 | 0 | 0 | 0 | ||
46 | 17 | 2 | 0 | 0 | 0 | |||||||
1 | E | 35 | 13 | 4 | 1 | 0 | 0 | |||||
35 | 13 | 4 | 1 | 0 | 0 | |||||||
2 | E | 22 | 13 | 9 | 5 | 2 | 0 | |||||
22 | 13 | 9 | 5 | 2 | 0 | |||||||
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT | BREAST | SXQOL | 1 | E | 31 | 13 | 9 | 3 | 1 | 0 | ||
31 | 13 | 9 | 3 | 1 | 0 | |||||||
2 | E | 30 | 12 | 8 | 4 | 1 | 0 | |||||
30 | 12 | 8 | 4 | 1 | 0 | |||||||
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction | SXQOL | OTHER | 1 | E | 10 | 6 | 5 | 3 | 1 | 0 | ||
10 | 6 | 5 | 3 | 1 | 0 | |||||||
NRGCC011-Breast, Survivors, Cog Training | SXQOL | 0 | E | 3 | 3 | 3 | 2 | 1 | 0 | |||
3 | 3 | 3 | 2 | 1 | 0 | |||||||
1 | E | 2 | 2 | 2 | 2 | 1 | 0 | |||||
2 | 2 | 2 | 2 | 1 | 0 | |||||||
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | GU | SXQOL | 1 | E | 14 | 6 | 4 | 1 | 1 | 1 | ||
14 | 6 | 4 | 1 | 1 | 1 | |||||||
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | GU | SXQOL | 1 | E | 9 | 8 | 1 | 0 | 0 | 0 | ||
9 | 8 | 1 | 0 | 0 | 0 | |||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | LUNG | SXQOL | 1 | E | 1 | 1 | 1 | 0 | 0 | 0 | ||
1 | 1 | 1 | 0 | 0 | 0 | |||||||
A021804-Adren, Advanced Stg, Temo w/wo Ola | GU | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | |||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
A031801-GU, mRCC, Cabozantinib +/- Radium-223 | GU | SXQOL | 1 | E | 15 | 5 | 2 | 1 | 0 | 0 | ||
15 | 5 | 2 | 1 | 0 | 0 | |||||||
A082002-Lung, Adv, Systemic Tx +/- SBRT | LUNG | SXQOL | 1 | E | 4 | 1 | 1 | 0 | 0 | 0 | ||
4 | 1 | 1 | 0 | 0 | 0 | |||||||
A191901-Brst, Text/Motivational Intervention ET Adher | CCD | 1 | E | 40 | 1 | 1 | 1 | 1 | 0 | |||
40 | 1 | 1 | 1 | 1 | 0 | |||||||
A211801-Breast, Preventive, Denosumab | PREV | 0 | E | 1 | 1 | 1 | 1 | 1 | 0 | |||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
1 | E | 1 | 1 | 1 | 1 | 1 | 0 | |||||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
A212102-Blind Ref Set for Multicancer Early Detection | PREV | 1 | E | 118 | 72 | 50 | 28 | 11 | 1 | |||
118 | 72 | 50 | 28 | 11 | 1 | |||||||
A222004-Mult, Olanza vs Megestrol for Anorexia | SXQOL | 1 | E | 6 | 4 | 3 | 3 | 3 | 1 | |||
6 | 4 | 3 | 3 | 3 | 1 | |||||||
A231602C-Blood Cancer, Assess Financial Difficulty | CCD | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | |||
4 | 0 | 0 | 0 | 0 | 0 | |||||||
A231901C-Breast, Shared Decision Engagement System | CCD | SXQOL | 1 | E | 2 | 1 | 0 | 0 | 0 | 0 | ||
2 | 1 | 0 | 0 | 0 | 0 | |||||||
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 1 | E | 2 | 2 | 2 | 1 | 0 | 0 | |||
2 | 2 | 2 | 1 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 1 | E | 2 | 1 | 0 | 0 | 0 | 0 | ||
2 | 1 | 0 | 0 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo | OTHER | SXQOL | 1 | T | 4 | 0 | 0 | 0 | 0 | 0 | ||
4 | 0 | 0 | 0 | 0 | 0 | |||||||
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad | GI | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 1 | 0 | ||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever | GI | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | ||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy | OTHER | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 1 | 0 | ||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
2 | E | 1 | 1 | 1 | 1 | 1 | 0 | |||||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
EA2182-Anal, Erly, DECREASE | GI | SXQOL | 0 | E | 13 | 6 | 1 | 1 | 1 | 0 | ||
13 | 6 | 1 | 1 | 1 | 0 | |||||||
1 | E | 14 | 6 | 1 | 1 | 1 | 0 | |||||
14 | 6 | 1 | 1 | 1 | 0 | |||||||
EA2185-Panc, Impact of Panc Cyst Surveillance | PREV | SXQOL | 1 | E | 19 | 5 | 1 | 0 | 0 | 0 | ||
19 | 5 | 1 | 0 | 0 | 0 | |||||||
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 1 | E | 13 | 3 | 1 | 1 | 0 | 0 | ||
13 | 3 | 1 | 1 | 0 | 0 | |||||||
2 | E | 0 | 0 | 0 | 0 | 0 | 0 | |||||
0 | 0 | 0 | 0 | 0 | 0 | |||||||
EA8184-Pros, Dbl Blind GTC vs Placebo | PREV | SXQOL | 0 | E | 16 | 11 | 7 | 4 | 2 | 1 | ||
16 | 11 | 7 | 4 | 2 | 1 | |||||||
1 | E | 6 | 4 | 2 | 2 | 0 | 0 | |||||
6 | 4 | 2 | 2 | 0 | 0 | |||||||
EA8191-Pros, Local vs Systemic Thrpy | GU | SXQOL | 0 | E | 43 | 22 | 16 | 14 | 3 | 0 | ||
43 | 22 | 16 | 14 | 3 | 0 | |||||||
1 | E | 43 | 22 | 16 | 14 | 3 | 0 | |||||
43 | 22 | 16 | 14 | 3 | 0 | |||||||
EA8212-Blad, NMIBC, BRIDGE | GU | SXQOL | 1 | E | 128 | 97 | 60 | 28 | 9 | 1 | ||
128 | 97 | 60 | 28 | 9 | 1 | |||||||
EAA173-MYEL, SMM, Rd +/- Daratumumab | MMYEL | SXQOL | 0 | E | 68 | 17 | 11 | 7 | 1 | 0 | ||
68 | 17 | 11 | 7 | 1 | 0 | |||||||
1 | E | 32 | 9 | 6 | 6 | 0 | 0 | |||||
32 | 9 | 6 | 6 | 0 | 0 | |||||||
EAQ202-Improving AYA PROs in EA Trials | SXQOL | 1 | E | 43 | 0 | 0 | 0 | 0 | 0 | |||
43 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGBN003-Mening, Grd II, Observation vs Irradiation | OTHER | SXQOL | 1 | E | 5 | 0 | 0 | 0 | 0 | 0 | ||
5 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 3 | 0 | 0 | 0 | 0 | 0 | |||||
3 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGBN011-Brain, Lomustine + Temo vs Temo | OTHER | SXQOL | 1 | E | 19 | 13 | 5 | 4 | 1 | 0 | ||
19 | 13 | 5 | 4 | 1 | 0 | |||||||
2 | E | 4 | 2 | 0 | 0 | 0 | 0 | |||||
4 | 2 | 0 | 0 | 0 | 0 | |||||||
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg | OTHER | SXQOL | 1 | E | 3 | 2 | 2 | 2 | 1 | 0 | ||
3 | 2 | 2 | 2 | 1 | 0 | |||||||
NRGBR007-Breast, Stg I, De-Escalation of Breast RT | BREAST | SXQOL | 1 | E | 9 | 4 | 1 | 1 | 0 | 0 | ||
9 | 4 | 1 | 1 | 0 | 0 | |||||||
2 | E | 9 | 4 | 1 | 1 | 0 | 0 | |||||
9 | 4 | 1 | 1 | 0 | 0 | |||||||
NRGBR009-Breast, EarlyStg, Adjuvant Chemo | BREAST | SXQOL | 1 | E | 4 | 4 | 4 | 1 | 1 | 0 | ||
4 | 4 | 4 | 1 | 1 | 0 | |||||||
2 | E | 3 | 3 | 3 | 0 | 0 | 0 | |||||
3 | 3 | 3 | 0 | 0 | 0 | |||||||
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs | PREV | 1 | E | 11 | 11 | 10 | 7 | 2 | 0 | |||
11 | 11 | 10 | 7 | 2 | 0 | |||||||
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO | PREV | SXQOL | 1 | E | 9 | 3 | 1 | 0 | 0 | 0 | ||
9 | 3 | 1 | 0 | 0 | 0 | |||||||
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy | GI | SXQOL | 1 | Y | 15 | 0 | 0 | 0 | 0 | 0 | ||
15 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT | GI | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 1 | 0 | ||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
2 | E | 1 | 1 | 1 | 1 | 1 | 0 | |||||
1 | 1 | 1 | 1 | 1 | 0 | |||||||
NRGGU009-Pros, PREDICT-RT | GU | SXQOL | 1 | E | 67 | 47 | 28 | 19 | 7 | 2 | ||
67 | 47 | 28 | 19 | 7 | 2 | |||||||
2 | E | 59 | 42 | 24 | 14 | 4 | 0 | |||||
59 | 42 | 24 | 14 | 4 | 0 | |||||||
NRGGU010-Pros, Parallel De-Intens & Intens Trials | GU | SXQOL | 1 | E | 40 | 22 | 10 | 7 | 0 | 0 | ||
40 | 22 | 10 | 7 | 0 | 0 | |||||||
2 | E | 36 | 22 | 8 | 5 | 0 | 0 | |||||
36 | 22 | 8 | 5 | 0 | 0 | |||||||
NRGGU013-Prostate, High-Risk, Five Fraction Radiation | GU | SXQOL | 1 | E | 2 | 2 | 2 | 2 | 0 | 0 | ||
2 | 2 | 2 | 2 | 0 | 0 | |||||||
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE | OTHER | SXQOL | 1 | E | 1 | 1 | 1 | 1 | 0 | 0 | ||
1 | 1 | 1 | 1 | 0 | 0 | |||||||
NRGHN005-HN, early stg P16-pos, randomize de-intensifi | OTHER | SXQOL | 1 | E | 8 | 1 | 0 | 0 | 0 | 0 | ||
8 | 1 | 0 | 0 | 0 | 0 | |||||||
NRGHN006-HN, Erly Stg, Biopsy vs Dissection | OTHER | SXQOL | 1 | E | 2 | 1 | 1 | 1 | 1 | 0 | ||
2 | 1 | 1 | 1 | 1 | 0 | |||||||
2 | E | 2 | 0 | 0 | 0 | 0 | 0 | |||||
2 | 0 | 0 | 0 | 0 | 0 | |||||||
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN | OTHER | SXQOL | 1 | E | 16 | 10 | 5 | 3 | 2 | 1 | ||
16 | 10 | 5 | 3 | 2 | 1 | |||||||
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux | OTHER | SXQOL | 1 | E | 6 | 0 | 0 | 0 | 0 | 0 | ||
6 | 0 | 0 | 0 | 0 | 0 | |||||||
2 | E | 5 | 0 | 0 | 0 | 0 | 0 | |||||
5 | 0 | 0 | 0 | 0 | 0 | |||||||
Study | Admin | CCAdmin | Registration/Phase | Open Date |
---|---|---|---|---|
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | MMYEL | SXQOL | 2 Randomization | 01-Dec-23 |
MMYEL | SXQOL | 3 Maintenance | 01-Dec-23 | |
A022004 Colon, Stg II-III, Encor+Cetux vs SOC | GI | SXQOL | 1 Registration | 30-May-23 |
A032103 Urothelial, All Stg, MRD-Based Adj Tx | GU | SXQOL | 2 Re-Registration | 09-Jan-24 |
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis | SXQOL | 2 Callback | 14-Aug-23 | |
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult | ERLYTX | SXQOL | 2 Late Randomization Callback | 08-May-17 |
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | GU | SXQOL | 2 Randomization2 | 08-Sep-17 |